USOR 24312 - Randomized study of BMS-986489 vs durvalumab in limited stage SCLC (TIGOS-LS)

An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)

Disease Types: Lung - Small Cell Lung

Available at: Arlington Heights, Chicago Resurrection, Niles